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ABSTRACT
Objectives: Cardiovascular disease is an important
comorbidity in patients with chronic obstructive
pulmonary disease (COPD). We aimed to systematically
review the evidence for: (1) risk of myocardial
infarction (MI) in people with COPD; (2) risk of MI
associated with acute exacerbation of COPD (AECOPD);
(3) risk of death after MI in people with COPD.
Design: Systematic review and meta-analysis.
Methods: MEDLINE, EMBASE and SCI were searched
up to January 2015. Two reviewers screened abstracts
and full text records, extracted data and assessed
studies for risk of bias. We used the generic inverse
variance method to pool effect estimates, where
possible. Evidence was synthesised in a narrative
review where meta-analysis was not possible.
Results: Searches yielded 8362 records, and 24
observational studies were included. Meta-analysis
showed increased risk of MI associated with COPD (HR
1.72, 95% CI 1.22 to 2.42) for cohort analyses, but
not in case–control studies: OR 1.18 (0.80 to 1.76).
Both included studies that investigated the risk of MI
associated with AECOPD found an increased risk of MI
after AECOPD (incidence rate ratios, IRR 2.27, 1.10 to
4.70, and IRR 13.04, 1.71 to 99.7). Meta-analysis
showed weak evidence for increased risk of death for
patients with COPD in hospital after MI (OR 1.13, 0.97
to 1.31). However, meta-analysis showed an increased
risk of death after MI for patients with COPD during
follow-up (HR 1.26, 1.13 to 1.40).
Conclusions: There is good evidence that COPD is
associated with increased risk of MI; however, it is
unclear to what extent this association is due to
smoking status. There is some evidence that the risk of
MI is higher during AECOPD than stable periods. There
is poor evidence that COPD is associated with
increased in hospital mortality after an MI, and good
evidence that longer term mortality is higher for
patients with COPD after an MI.
INTRODUCTION
Cardiovascular disease is a common
comorbidity and cause of death in people
with chronic obstructive pulmonary disease
(COPD), with up to one-third dying of car-
diovascular disease.1 Reducing the cardiovas-
cular disease in this population is an
important strategy for reducing the burden
of COPD.
Several studies have shown that people
with COPD have a higher risk of myocardial
infarction (MI) than people without
COPD.2–4 One of the reasons for the
increased risk of MI in patients with COPD is
the shared major risk factor of smoking. In
addition, several other cardiovascular risk
Strengths and limitations of this study
▪ This systematic review investigated three import-
ant areas relating to the relationship between
chronic obstructive pulmonary disease (COPD)
and cardiovascular disease: (1) the risk of myo-
cardial infarction (MI) associated with COPD; (2)
the risk of MI associated with acute exacerba-
tions of COPD; and (3) the risk of death follow-
ing MI in patients with COPD compared to
patient without COPD.
▪ Strengths of this review were the wide search
strategy, broad inclusion criteria and rigorous
risk of bias assessment of included studies.
▪ We found strong evidence for an increased risk
of MI in people with COPD and an increased risk
of longer term death after MI for patients with
COPD; however, it is unclear how much of this
increased risk may be due to smoking status.
▪ We found poorer evidence for an increased risk
of MI during periods of acute exacerbation of
COPD compared to stable periods, and for an
increased risk of death in hospital after MI for
patients with COPD. We make recommendations
on how future studies can improve our under-
standing of these relationships.
▪ Due to statistical and clinical heterogeneity,
meta-analysis could only be conducted for some
of the research questions.
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factors, including hypertension, diabetes, inactivity, poor
diet, and older age, are also prevalent in patients with
COPD.5–7 In addition, several studies have found an
association between reduced FEV1 (forced expiratory
volume1 s) and cardiovascular mortality in the general
population.8 However, COPD itself is also thought to be
an independent risk factor for MI with increased risk of
MI possibly being mediated through increased systemic
inﬂammation or reduced FEV1 in people with COPD.
Acute exacerbations of COPD are events in the
natural history of COPD which are characterised by an
increase in COPD symptoms such as breathlessness,
cough, sputum volume, and sputum purulence. It has
recently been suggested that acute exacerbations of
COPD (AECOPD) represent a period of increased risk
of MI for people with COPD.9 A subtype of patients with
COPD appears to have more frequent exacerbations
than others. Frequent exacerbators have been deﬁned
as individuals who have two or more treated exacerba-
tions per year. Frequent exacerbators may be at higher
risk of MI compared to infrequent exacerbators, even
during stable periods.
Several investigators have found that patients with
COPD have worse mortality in hospital and following dis-
charge after an MI compared to patient without
COPD.10–12 However, the ﬁnding that patients with
COPD have greater in hospital and short-term mortality
has not been found by all investigators.13–15
We aimed to systematically review the literature report-
ing on: (1) the risk of MI in people with COPD; (2) the
risk of MI associated AECOPD, either during AECOPD
or that associated with the frequent exacerbator pheno-
type; and (3) the risk of death after MI in people with
COPD. These questions represent the most salient
aspects of current research into the relationship
between COPD and cardiovascular disease, and no sys-
tematic reviews have been published on these topics to
date.
METHODS
Literature search
MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, BIOSIS & Science Citation Index
were searched up to January 2015. A search strategy was
devised which would pick up articles relevant to all
three research questions. All strategies were based on
the MEDLINE search strategy, which is presented in the
online supplementary material. In brief, the literature
was searched for terms which relate to COPD and terms
with relate to MI, and these searches were combined
using the AND Boolean logic operator. MeSH terms
were combined with natural language searching using
truncation where appropriate.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were applied for each of
the three research questions. Studies were included if
they met the population, exposure, comparator and
outcome criteria. These are presented below for each
research question. Studies were included from database
start date and were not restricted by language.
Risk of MI in people with COPD
The population of interest was the general population.
The exposure of interest was diagnosis of COPD. The
un-exposed group was people without a diagnosis of
COPD. The outcome of interest was acute MI.
Risk of MI associated with AECOPD
The population of interest was people with a diagnosis
of COPD. The exposures of interest were either: (1) dis-
crete episodes of AECOPD or periods within 8 weeks of
an AECOPD; or (2) frequent exacerbator phenotype.
The comparators of interest were either: (1) periods of
stable COPD; or (2) infrequent exacerbator phenotype.
Studies were included if these reported a relative risk of
MI, or if this could be calculated.
Risk of death after MI in people with COPD
The population of interest was those presenting to a hos-
pital with an MI. Studies were included if these com-
pared patients with a diagnosis of COPD to those
without a diagnosis of COPD. Outcomes of interest were
death in hospital and at any reported time points post
discharge. Studies investigating risk of death for patients
with COPD after an interventional procedure following
an MI (such as percutaneous coronary intervention or
coronary artery bypass graft) were speciﬁcally excluded
under the population criterion.
Selection of included studies
Titles and abstracts, where available, were initially
screened for potential inclusion by one reviewer. Full
text versions of potentially included studies were then
obtained and were screened by two reviewers. Authors
were contacted if the information provided in articles
was not sufﬁcient to assess whether inclusion criteria
were satisﬁed.
Risk of bias assessment
All included studies, except for those only reported as
conference abstracts, were assessed for risk of bias. The
risk of bias tool was informed by the Newcastle-Ottawa
scale;16 however, we did not make use of a summary
score as this is not advisable.17 18 Risk of bias was
assessed across the key domains related to selection of
participants, comparability of groups, and measurement
of outcomes. Several items were included under each
domain, and were adapted for different study types.
Where reports of studies included more than one ana-
lysis (eg, a case control as well as a cohort analysis) the
risk of bias for these analyses were conducted separately.
Risk of bias assessment was completed by one reviewer
and checked by another.
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Evidence synthesis
Characteristics and ﬁndings of studies were tabulated
and compared. Data on severity of COPD was extracted
as GOLD stage or FEV1% predicted, where available.
Information was also extracted on smoking status and
previous cardiovascular disease. Estimates of effect were
extracted or calculated, and are presented as ORs, risk
ratios (RR), incidence rate ratios (IRR) or HRs.
Where included studies were reasonably statistically
and clinically similar, we pooled results using random
effects meta-analysis. We used the generic inverse
variance method to pool maximally adjusted effect esti-
mates. Analysis was conducted in Review Manager 5.3.
Where studies were too statistically (I2 over 75%) or clin-
ically heterogeneous, meta-analysis was not conducted,
but study summary results were graphed on forest plots
without pooling the results. Studies which were not
adjusted at all were not included in forest plots. For the
question on risk of MI associated with COPD, studies
were stratiﬁed by adjustment for smoking status (yes or
no) and study design (cohort or case–control). For the
question on risk of death following MI in COPD com-
pared to patient without COPD, studies were stratiﬁed
by outcome time point (in-hospital mortality or
follow-up mortality). For follow-up mortality, studies
were further stratiﬁed by analysis.
RESULTS
Identified studies
Literature searches yielded 8362 records. After title and
abstract screening, 49 records were selected for full-text
assessment, which resulted in the inclusion of 24 studies.
The inclusion and exclusion process is summarised in
ﬁgure 1. Of the 24 included studies, 9 investigated the
risk of MI in patients with COPD compared to patient
without COPD; 2 investigated the risk of MI associated
with AECOPD; no studies were found which investigated
the risk of MI associated with the frequent exacerbator
phenotype; and 12 investigated outcomes after MI for
patients with COPD compared to patient without COPD.
Summary characteristics of included studies are pre-
sented in tables 1–3.
All of the included studies which investigated risk of
MI in people with COPD used data from either routine
clinical or administrative databases. COPD was deﬁned
using diagnostic codes; these varied between COPD
diagnosis in primary care, outpatient departments, hos-
pital admission or discharge codes, and cause of death
codes. Three studies also required that patients with
COPD had been prescribed COPD medicines. One of
the studies, Rodriguez et al,19 included only patients with
a recent diagnosis of COPD and followed up to 5 years
after this diagnosis to identify MI. Only one study3
reported a summary of COPD severity, and only two
reported prevalence of current smokers. Four studies
reported a cohort analysis only. Two studies4 19 reported
a cohort analysis as well as a case–control analysis. One
study reported the results of a cohort analysis and an
analysis of period prevalence. One study20 compared
rates of MI in patients with COPD to standardised popu-
lations rates of MI.
Two studies9 21 were identiﬁed which investigated the
risk of MI associated with AECOPD. Both studies
deﬁned risk periods after the onset of AECOPD and
used within person designs to compare the risk to a
baseline period.
Nine studies reported mortality for patients with COPD
after an MI compared to patient without COPD. Five
studies11 12 14 15 22 reported a comparison of in-hospital
mortality after an MI between patients with COPD and
patient without COPD. Eight studies10 12 13 23–27 used a
time-to-event analysis to investigate death after discharge
from a hospital admission for MI.
Risk of bias assessment
The proportion of studies (or analyses, where appropri-
ate) which were assessed as having either lower, unclear
or higher risk of bias for each of the research questions
is presented in ﬁgure 2. Detailed results from the risk of
bias assessment for individual studies are presented in
the appendix.
Risk of MI in people with COPD
Of nine included studies, eight found a higher risk of
MI in patients with COPD compared to patient without
COPD. Six studies estimated the ratio of incidence rates
of MI in patients with COPD compared to patient
without COPD. Five studies4 19 20 28 29 estimated this for
all MIs, this ranged from IRR 1.18 (95% CI 0.81 to 1.71)
to 5.31 (4.54 to 6.21). One study2 30 estimated the IRR
for hospitalisation due to MI (IRR 1.49, 95% CI 0.71 to
3.13) and fatal MIs (1.51, 1.14 to 2.01). Two studies31 32
estimated the ratio of hazard of MI in patients with
COPD compared to patient without COPD one study
Figure 1 Study selection. AECOPD, acute exacerbation of
COPD; COPD, chronic obstructive pulmonary disease;
MI, myocardial infarction.
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Table 1. Characteristics of included studies – risk of MI associated with COPD
Study
Design and
setting Population
Characteristics
of COPD patients MI definition
Maximally adjusted
estimate (95% CI) Factors adjusted for
Curkendall
et al 2 30
Cohort in the
Saskatchewan
Health databases
1998–2001.
11 493 COPD patients
≥40 years, identified by
physician claim or
hospital discharge COPD
code and at least two
prescriptions for COPD
medicines within 6
months of the index
COPD code.
22 986 age and sex
matched non-COPD
patients
Age
NR
Sex
NR
COPD severity
NR
Current smokers
16%
History of CVD
Previous
MI—2.3%
Previous
angina—6.6%
Any MI during follow up:
any inpatient or
outpatient diagnosis
of MI
Hospitalisation due to
MI: primary hospital
discharge diagnosis
of MI
Fatal MI: underlying
cause of death which
initiated the sequence of
events that lead to death
recorded as MI
Any MI during follow up
(period prevalence): OR
1.61 (1.43–1.81)
Hospitalisation due to
MI: IRR 1.49 (0.71–3.13)
Fatal MI: IRR 1.51
(1.14–2.01)
Period prevalence of MI: Age,
sex, history of cardiovascular
disease, diabetes,
hypertension,
hypercholesterolaemia
Hospitalisation for MI: adjusted
for history of cardiovascular
events, diabetes, hypertension,
and hypercholesterolemia using
Poisson regression, age and
sex by matching.
Fatal MI: age and sex by
matching only.
Feary et al 3 Cohort in The
Health Improvement
Network,
2005–2007
29 870 COPD patients
>35 years identified by
COPD diagnostic code.
1 174 240 non-COPD
patients
Age
35–44–1.8%
45–54–7.0%
55–64–20.5%
65–74–31.7%
≥75–39.0%
Sex
48.1% male
COPD severity
FEV1 % predicted
50–80%–37.5%
30–49%–19.1%
<30%–5.3%
Current smokers
65.3%
History of CVD
Prior CVD–28.0%
Diagnostic code for MI
in primary care record
35–44 years:
HR 10.34 (3.28–32.6)
45–54 years:
HR 1.22 (0.55–2.74)
55–64 years:
HR 1.55 (1.07–2.26)
65–74 years:
HR 1.78 (1.37–2.31)
≥75 years:
1.34 (1.03–1.73)
Age, sex and smoking status
Continued
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Table 1. Continued
Study
Design and
setting Population
Characteristics
of COPD patients MI definition
Maximally adjusted
estimate (95% CI) Factors adjusted for
Huiart et al 28 Cohort in the
Saskatchewan
Health databases
1990–1999
5 648 COPD patients
≥50 years, identified by
prescription of three or
more bronchodilators
within the period of one
year.
Rates of MI compared to
those of general
Saskatchewan population
Age
NR
Sex
NR
COPD severity
NR
Current smokers
NR
History of CVD
NR
Characteristics
were not split by
COPD status.
Primary hospital
discharge diagnosis of
MI
Standardised IRR: 1.30
(1.15–1.44)
Age and sex by standardisation
Mapel et al 28 Cohort in the
Veterans
Administration
Medical System,
1991–1999
COPD patients identified
by discharge codes
(1991–1999) and/or
outpatient codes
(1997–1999)
Age and sex matched
controls without COPD
Age
Median 60 (IQR,
49–62)
Sex
95.7% male
COPD severity
NR
Current smokers
NR
History of CVD
Cardiovascular
disease—71.2%
Specific ICD-9-CM code
for MI during 1999 that
was not present in 1998
COPD patients identified
using discharge codes
IRR: 1.28 (1.18–1.38)
COPD patients identified
using outpatient codes
IRR: 5.31 (4.54–6.21)
Age and sex by matching
Rodriguez
et al 19
Cohort and
case-control study
in the General
Practice Research
Database,
1996–2001
1532 patients with a first
COPD diagnosis in 1996,
and no history of
cardiovascular disease
13 500 age and sex
matched non-COPD
patients, with no history
of cardiovascular disease
Age
NR
Sex
NR
COPD severity
NR
Current smokers
NR
History of CVD
NR
Diagnostic code for MI
in primary care record
Cohort analysis:
IRR 1.18 (0.81–1.71)
Case-control analysis: OR
0.93 (0.62–1.39)
Cohort analysis:
Age and sex
Case control analysis:
Age, sex, smoking and number
of primary care physician visits
Continued
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Table 1. Continued
Study
Design and
setting Population
Characteristics
of COPD patients MI definition
Maximally adjusted
estimate (95% CI) Factors adjusted for
Schneider
et al 4
Cohort and nested
case-control study
in the General
Practice Research
Database, 1995–
2005
35 772 patients with a
first COPD diagnosis
between 1995–2005
35 772 non-COPD
patients matched on age,
sex and calendar time
and general practice
Age
40–49–6.8%
50–59–19.9%
60–69–33.8%
>70–39.6%
Sex
51.3% male
COPD severity
NR
Current smokers
43.3%
History of CVD
Prior
MI/CHD—18.3%
Prior CHF—8.4%
Diagnostic code for MI
along with death or
hospitalisation within 30
days of the diagnosis;
and/or start of new
treatment with ACE
antagonist, β-blocker,
statin, vitamin K
antagonist, platelet
aggregation inhibitor or
aspirin within 90 days of
the diagnosis in primary
care record
Cohort analysis:
IRR 1.56 (1.43–1.75)
Case control analysis:
Any COPD :
OR 1.40 (1.13–1.73)
Mild COPD:
OR 1.79 (1.12–2.86)
Moderate COPD:
OR 1.30 (1.04–1.62)
Severe COPD:
OR 3.00 (1.53–5.86)
Cohort analysis: matched on
age, sex, calendar time and
general practice
Case-control analysis: Smoking
status, BMI, hypertension,
hyperlipidaemia, diabetes and
NSAID use
Sidney
et al 29
Cohort in health
insurance
database. North
Carolina, 1996–
1999
COPD defined as:
hospitalisation or
outpatient diagnosis of
COPD, two or more
prescriptions for COPD
medicines, aged over 40
years.
Non-COPD patients
matched on age, sex and
length of care plan
membership.
Age
40–59–35%
60–79–55%
>80–10%
Sex
55.4% male
COPD severity
NR
Current smokers
NR
History of CVD
Prior MI—1.8%
Prior
angina—1.0%
Prior
CHF—7.2%
ICD code for acute MI Overall:
IRR 1.89 (1.71–2.09)
Men:
IRR 1.77 (1.56–2.01)
Women:
IRR 2.09 (1.78–2.46)
40–64 years:
IRR 2.43 (1.98–2.98)
≥65 years:
IRR 1.73 (1.54–1.94)
Age, sex and baseline
cardiovascular risk profile.
Sode et al 31 Cohort study within
the National Danish
patient registry,
1980–2006
Entire Danish population.
COPD identified through
hospital admission codes
or COPD as cause of
death
Age
<30–7%
30–59–54%
60–79 –35 %
>80–3%
Discharge diagnosis of
MI or cause of death
from Danish Causes of
Death Registry listed as
MI
HR 1.26 (1.25–1.27) Age, sex, Danish ancestry,
geographical residency
(rurality), and level of education
Continued
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Table 1. Continued
Study
Design and
setting Population
Characteristics
of COPD patients MI definition
Maximally adjusted
estimate (95% CI) Factors adjusted for
Sex
55% male
COPD severity
NR
Current smokers
NR
History of CVD
NR
Yin et al 32 Cohort of all
residents of
Sweden aged over
18, July 2005-
December 2008.
51 348 COPD patients
identified by diagnostic
codes from patient
records. 6 743 342
non-COPD patients.
Those with no
previous MI or
stroke
Age
Mean 71.1
Sex
44.3% male
COPD severity
NR
Current smokers
NR
History of CVD
No previous MI
Those with
previous MI
Age
Mean 69.2
Sex
58.4% male
COPD severity
NR
Current smokers
NR
History of CVD
All had previous
MI
Diagnostic code for MI,
or primary cause of
death listed as MI
No previous MI or stroke:
HR 1.47 (1.41–1.55)*
Previous MI:
HR 1.33 (1.23–1.43)*
Age, sex, socioeconomic
status, use of cardiovascular
and respiratory medicines.
*Data from personal communication (Magnus Back. Email communication. 18/08/2014).
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FEV1, forced expiratory volume in 1 s; ICD, International Classification of Diseases; IRR, incidence rate ratios;
MI, myocardial infarction.
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estimated this to be HR 1.26 95%, CI 1.25 to 1.27, while
the other study estimated this to be HR 1.47 (1.41 to
1.55) for those with no previous MI, and HR 1.33 (1.23
to 1.43) for those with a previous MI. One study2 30 esti-
mated the ratio of odds of period prevalence over
5 years of acute MI in patients with COPD compared to
patient without COPD (OR 1.61, 95% CI 1.43 to 1.81).
Only one3 of the included cohort studies compared risk
of MI in people with COPD and people without COPD
adjusted for smoking status. This study reported results
stratiﬁed by age groups. Meta-analysis of these results
showed an increased risk of MI for people with COPD
(HR 1.72, 95% CI 1.22 to 2.42) (ﬁgure 3). Two of the
included case–control studies adjusted for smoking
status. Meta-analysis of these results did not show an
increased risk of MI for people with COPD (OR 1.18,
95% CI 0.80 to 1.76) (ﬁgure 4). Meta-analysis was not
conducted for the studies which did not adjust for
smoking as heterogeneity was too high (I2=93%). These
results are graphically summarised in ﬁgure 5.
Some studies investigated whether the effect of COPD
on the risk of MI was different in terms of age and sever-
ity of airﬂow obstruction. Feary et al3 found that
the effect of COPD on risk of MI was higher in the
35–44 year age group (HR 10.34, 95% CI 3.28 to 32.6)
compared to older age groups (45–54 years: HR 1.22
(95% CI 0.55–2.74), 55–64 years: HR 1.55 (95% CI 1.07
to 2.26), 65–74 years: HR 1.78 (95% CI 1.37 to 2.31),
≥75 years: HR 1.34 (95% CI 1.03 to 1.73)). Sidney
200529 reported similar ﬁndings; the effect of COPD on
risk of MI was higher in those who were aged
40–64 years (HR 2.43, 95% CI 1.98 to 2.98) compared to
those who were aged over 64 years (HR 1.73, 95% CI
1.54 to 1.94). Schneider et al4 investigated the risk of MI
by sub-group of COPD severity. They found that the
effect of COPD on the risk of MI was greater in those
with severe COPD (OR 3.00, 95% CI 1.53 to 5.86) com-
pared to those with moderate COPD (OR 1.30, 95% CI
1.04 to 1.62) or mild COPD (OR 1.79, 95% CI 1.12
to 2.86).
Risk of MI associated with AECOPD
Donaldson 20109 conducted a self-controlled case series
using data from The Health Improvement Network
(THIN). They used prescription of antibiotics and ster-
oids in patient with COPD to identify AECOPD, and
report an increased risk of MI in the 1–5 days following
the onset of AECOPD (IRR 2.27, 95% CI 1.10 to 4.70).
No difference in the risk of MI was found for the period
6–49 days, or at any time point when the alternative deﬁ-
nitions of AECOPD of prescription of steroids alone or
antibiotics alone were used. Halpin et al21 reported a sec-
ondary analysis of the UPLIFT trial, which was an RCT
comparing inhaled tiotropium and placebo in patients
with COPD with a primary outcome of reduction in
FEV1 decline. Time to ﬁrst AECOPD was a secondary
outcome. AECOPD were identiﬁed using a symptom-
based deﬁnition and were reported to trial staff at
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Table 3. Characteristics of included studies – risk of death after MI
Study Design and setting Population
COPD patient
characteristics
Maximally adjusted
estimate for mortality
(95% CI) Factors adjusted for
Andell
et al 10
Cohort study within the
Swedish SWEDEHEART
registry between 2005–2010.
Consecutive patients admitted to
Swedish coronary care units. COPD
diagnosis ascertained through
linkage to the Swedish National
Patient Registry.
Age
Mean 75 years
(SD, 9)
Sex
54% male
COPD severity
NR
Current smokers
32.9%
History of CVD
Prior MI 13.7%
Prior HF 20.2%
Mortality at one year:
HR 1.14 (1.07–1.21)
Age, sex, smoking, comorbidity
(previous MI, previous stroke, heart
failure, renal failure, hypertension,
diabetes, peripheral artery disease,
cancer and previous bleeding), in
hospital treatment and discharge
medications (heparin,
fondaparinux, dalteparin,
enoxaparin, glycoprotein IIb/IIa
inhibitors, angioplasty, coronary
stenting, β-blockers, aspirin,
clopidogrel, prasugrel, calcium
channel blockers, digoxin,
diuretics, statins, nitrates and
warfarin).
Behar
et al 22
Cohort study in Israel between
1981–1983
2276 consecutive patients surviving
an MI after admission to 13
coronary care units. Patients with a
history of chronic bronchitis or
chronic airways obstruction and
clinical and/or radiographic findings
compatible with COPD during
hospitalisation for MI were included.
Age
Mean 66.8 years
(SD, 9.7)
Sex
79.3% male
COPD severity
NR
Current smokers
43.3%
History of CVD
Prior MI—28.8%
Prior angina—55.4%
Unadjusted:*
In –hospital RR 1.39
(1.16–1.67)
1 year RR 1.34
(1.16–1.55)
5 years RR 1.28
(1.18–1.40)
Bursi et al 23 Cohort study of the population
in the Rochester Epidemiology
project involving residents in
Olmsted County, Minnesota
from 1979 to 2007
Local residents in Olmsted County.
MI ascertained from medical
records compatible with ICD
criteria. Information on COPD was
also obtained from ICD codes.
Age
Mean 73 years
(SD, 11)
Sex
59% male
COPD severity
NR
Current smokers
35%
History of CVD
Those with prior CVD
excluded
HR 1.30 (1.10 to 1.54),
mean follow up 4.7 years.
Age, sex, smoking, hypertension,
MI type (STEMI/non-STEMI),
creatine kinase level,
killip class, reperfusion treatment in
hospital, use of drugs on discharge
(β-blockers, ACEi, diuretics)
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Table 3. Continued
Study Design and setting Population
COPD patient
characteristics
Maximally adjusted
estimate for mortality
(95% CI) Factors adjusted for
Dziewierz
et al 24
Cohort study within Krakow
Registry of ACS in February
2005-March 2005 and
December 2005-January 2006
1414 patients with MI admitted to
hospital in Krakow, Poland. Those
with a previous history of COPD
and current treatment with a steroid
or bronchodilator were classified as
COPD patients.
Age
Mean 71.8 years
(SD, 11)
Sex
62% male
COPD severity
NR
Current smokers
40.7%
History of CVD
MI 34.6%
Angina 80.2%
HF 30.9%
HR 2.15 (1.30–3.55) Age, sex, BMI, diabetes,
hypertension, hyperlipidaemia,
prior angina, prior MI, prior heart
failure, left ventricular ejection
fraction, prior PCI, prior CABG,
prior stroke or transient ischaemic
attack, smoking status, peripheral
arterial disease, chronic renal
insufficiency, parameters on
admission (chest pain,
cardiogenic shock, heart rate,
systolic blood pressure, diastolic
blood pressure), time from chest
pain onset to admission and type
of MI (STEMI or NSTEMI)
Enriquez
et al 11
Cross sectional study of
National Cardiovascular Data
Registry in the USA between
January 2008 and December
2010
158 890 patients admitted to one of
445 sites with an MI. COPD
patients had a history of COPD or
were using long term inhaled or oral
β-agonists, inhaled
anti-inflammatory agents,
leukotriene receptor antagonists or
inhaled steroids.
Age
STEMI—median
66 years
nSTEMI—median
70 years
Sex
STEMI—60.4% male
nSTEMI—57.5%
male
COPD severity
NR
Current smokers
STEMI—57.0%
nSTEMI—41.9%
History of CVD
STEMI
Prior MI—29.7%
Prior CHF—15.3%
nSTEMI
Prior MI—39.%
Prior CHF—33.3%
In-hospital mortality
STEMI OR 1.05
(0.95–1.17)
Non-STEMI OR 1.21
(1.11–1.33)
Age, serum creatinine, systolic
blood pressure, troponin elevation,
heart failure or cardiogenic shock
at presentation, ST-segment
changes, heart rate and prior
peripheral arterial disease.
Continued
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Table 3. Continued
Study Design and setting Population
COPD patient
characteristics
Maximally adjusted
estimate for mortality
(95% CI) Factors adjusted for
Hadi et al 15 Cross sectional study of
patients hospitalised with ACS
in May 2006 and January
2007 to June 2007 in six
Middle Eastern countries
8169 consecutive patients in the
Gulf RACE registry presenting with
ACS at 65 centres across six
countries. COPD patients were
identified from 1) medical records or
2) use of COPD medicines.
Age
Median 64
(IQR, 56–71)
Sex
NR
COPD severity
NR
Current smokers
38.7%
History of CVD
Prior MI—34.8%
Prior angina – 54.4%
In hospital mortality:
OR 0.40 (0.20–1.24)
Age, sex, cardiogenic shock, use
of thrombolysis, use of aspirin, use
of β-blocker, use of ACEi
Hawkins
et al 25
Cohort study of patients with
acute MI enrolled in VALIANT
trial
Patients with MI complicated by
LVSD and HF. COPD was identified
by a questionnaire completed by
trial site investigators.
Age
Mean 68.1 (SD, 9.9)
Sex
71.1% male
COPD severity
NR
Current smokers
42.0%
History of CVD
Prior MI—39.9%
Prior angina—46.1%
Prior HF—27.3%
HR 1.14 (1.02–1.28) Age, heart rate, systolic and
diastolic blood pressure, weight,
baseline creatinine, smoking
status, diabetes, dyslipidaemia,
hypertension, killip classification,
anterior MI, new lower bundle
branch block, thrombolytic therapy,
primary PCI, coronary artery
bypass graft, history of heart
failure, atrial fibrillation, previous
MI, angina, previous stroke,
peripheral arterial disease, renal
insufficiency, alcohol abuse,
country of enrolment, beta blocker
use, randomised treatment
Kjoller
et al 13
Cohort study of consecutive
patients recruited 1–6 days
after an MI
Danish hospitals between May
1990 and July 1992 as part of
TRACE study. COPD was identified
using either 1) medical records or
2) patient report in addition to use
of COPD medicines
Age
Median 70.5
(5–95 percentiles,
50.7–83.5)
Sex
68.2% men
COPD severity
NR
Current smokers
60.0%
History of CVD
Previous MI—25.1%
Cohort entry to 30 days:
HR 0.89 (0.68–1.11)
Cohort entry to 7 years:
HR 1.15 (1.04–1.28)
Age, sex, BMI, hypertension,
diabetes, smoking status, previous
angina, wall motion index, angina,
history of CHF, new CHF, atrial
fibrillation, bundle branch block,
wall motion index, use of
thrombolytic therapy
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Table 3. Continued
Study Design and setting Population
COPD patient
characteristics
Maximally adjusted
estimate for mortality
(95% CI) Factors adjusted for
Previous
angina—43.9
Previous
CHF—28.2%
Quint et al 26
(abstract)
Cohort study of patients
admitted after a first MI using
data from the UK CALIBER
database
8 065 patients admitted to UK
hospitals with a first MI between
Jan 2003-Dec 2008. COPD was
identified using primary care
records.
Age
NR
Sex
NR
COPD severity
NR
Current smokers
NR
History of CVD
NR
Mortality up to 7 years:
HR 1.37 (1.23–1.52)
Age and sex
Raposeiras
et al 12
(abstract)
Cross sectional and cohort
study of patients with ACS
4 497 consecutive patients admitted
to Spanish hospitals for ACS. The
ascertainment method for COPD
was unclear.
Age
NR
Sex
NR
COPD severity
NR
Current smokers
NR
History of CVD
NR
In-hospital death
OR 1.04 (1.03–1.04)
Follow up mortality
HR 1.69 (1.41–2.03),
median follow up 3.1
years
GRACE score
β-blocker therapy
Rha et al 33
(abstract)
Case control study in Korea
AMI registry from 2005 to
2007
AMI patients in KAMIR Age
Mean 71.7 (SD 10.0)
Sex
NR
COPD severity
NR
Current smokers
NR
History of CVD
NR
Mortality at 8 months
OR 2.69, 95% CI could
not be calculated from
reported information.
Unadjusted
Salisbury
et al 27
19 centre prospective study of
patients presenting with MI in
a cohort study
MI patients in PREMIER study
restricted to patients discharged
alive after MI. Patients were
considered to have COPD if they
had a documented history of
Age
Mean 64.5 (SD, 12.4)
Sex
61.8% male
COPD severity
Mortality up to 1 year
HR 2.00 (1.44–2.79)
Age, gender, race, avoidance of
health care due to cost, smoking,
diabetes, hypertension, CHF,
ejection fraction, previous CVD, MI
diagnosis type, new onset HF after
Continued
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Table 3. Continued
Study Design and setting Population
COPD patient
characteristics
Maximally adjusted
estimate for mortality
(95% CI) Factors adjusted for
obstructive pulmonary disease
(COPD or asthma) or had therapy
specific for obstructive pulmonary
disease.
NR
Current smokers
37.6%
History of CVD
Previous MI—29.7%
Previous HF—24.3%
MI, diseased vessels on
angiogram, enrolling site,
percentage of MI quality of care
indicators of the centre, treatment
type
Stefan
et al 14
Cross sectional study with
follow up of patients
hospitalised with AMI at
greater Worcester,
Massachusetts between
1997–2007
Patients hospitalised with AMI in
greater Worcester, Massachusetts
medical centres. COPD patients
were identified by previous mention
of clinical or radiographic evidence
for COPD in their medical record.
Age
Mean 74 years
Sex
52.4% male
COPD severity
NR
Current smokers
27.3%
History of CVD
Prior angina—22.3%
Prior HF—38.6%
In hospital: OR 1.25
(0.97–1.34)
30 day mortality: OR 1.31
(1.10–1.58)
Age, sex, year of hospitalisation,
history of CVD, history of renal
failure, type of MI (STEMI/
non-STEMI), length of stay,
smoking status used in secondary
analysis
*Calculated from reported data.
AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HF, heart failure;
LVSD, left ventricular systolic dysfunction; MeSH, Medical Subject Headings; MI, myocardial infarction; NR, not reported; PCI, percutaneous coronary intervention; NSTEMI, non–ST-segment
elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
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regular study visits. Data on MI were collected as serious
adverse events. This study found that compared to the
30 days prior to AECOPD, risk of MI in the 30 days fol-
lowing AECOPD was increased (IRR 13.04; 95% CI 1.71
to 99.7). These results are graphically summarised in
ﬁgure 6. Owing to different exposure time periods, the
results for within person studies investigating the risk of
MI associated with AECOPD were not pooled in
meta-analysis.
Risk of death after MI in people with COPD
Of the studies investigating differences in in-hospital
mortality after an MI, two12 22 found an increased risk of
mortality for patients with COPD (RR 1.39, 95% CI 1.16
to 1.67 (unadjusted); and OR 1.04, 95% CI 1.03 to
1.04). Two studies14 15 did not ﬁnd evidence for
increased in-hospital mortality for patients with COPD
(OR 0.40, 95% CI 0.20 to 1.24; OR 1.25, 95% CI 0.97 to
1.34). One study11 reported results split by type of MI: it
Figure 2 Summary of risk of bias for risk assessments for: A studies investigating risk of MI associated with COPD; B studies
investigating risk of MI associated with AECOPD; and C studies investigating risk of death following MI in people with COPD.
AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
Figure 3 Forest plot showing risk of MI associated with COPD in cohort studies which adjusted for smoking status. CIs may
vary slightly from those quoted in tables due to transformation during meta-analysis. COPD, chronic obstructive pulmonary
disease; MI, myocardial infarction.
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did not ﬁnd an increased in-hospital mortality for
patients with COPD after a STEMI (OR 1.05, 95% CI
0.95 to 1.17), but did ﬁnd increased in-hospital death
for patients with COPD after a non-STEMI (OR 1.21,
95% CI 1.11 to 1.33). Meta-analysis of adjusted results
showed weak evidence for an increased risk of
in-hospital death for patients with COPD (OR 1.13, 95%
CI 0.97 to 1.31) (ﬁgure 7).
One study14 reported mortality at 30 days for patients
with COPD compared to patient without COPD. This
study found increased mortality for patients with COPD
(OR 1.31, 1.10 to 1.58). Another study33 reported mor-
tality at 8 months, and in an unadjusted analysis, found
increased mortality for patients with COPD compared to
patients without COPD (OR 2.69, 95% CI was not
reported and could not be calculated). One study22 also
found, on unadjusted analysis, that mortality was greater
for patients with COPD at 1 year (RR 1.34, 95% CI 1.16
to 1.55) and 5 years (RR 1.28, 95% CI 1.18 to 1.40)
after MI.
Eight studies10 12 13 23–27 reported results of survival
analysis of mortality during follow-up after an MI. All of
the studies reported higher mortality for patients with
COPD compared to patients without COPD during
follow-up after discharge following an MI. HRs ranged
from 1.15 (95% CI 1.04 to 1.28) to 2.15 (95% CI 1.30 to
3.55). However, one of these studies13 found no evi-
dence of a difference in mortality when restricting the
time period to the ﬁrst 30 days following discharge (HR
0.89, 95% CI 0.68 to 1.11). Meta-analysis of studies
which reported adjusted results showed an increased
risk of death after discharge following MI for patients
with COPD compared to patients without COPD (HR
1.26, 1.13 to 1.40) (ﬁgure 8). Four of the studies
included under this question were excluded from
meta-analysis for methodological12 33 or clinical
heterogeneity.25 27
DISCUSSION
Main findings
Most studies which investigated the risk of MI in people
with COPD found that those with COPD have higher
risk of MI than people who do not have COPD; however,
Figure 5 Forest plot showing risk of MI associated with COPD in cohort studies which did not adjust for smoking status. CIs
may vary slightly from those quoted in tables due to transformation during meta-analysis. COPD, chronic obstructive pulmonary
disease; MI, myocardial infarction.
Figure 6 Forest plot showing risk of MI associated with acute exacerbations of COPD. CIs may vary slightly from those quoted
in tables due to transformation during meta-analysis. COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
Figure 4 Forest plot showing risk of MI associated with COPD in case-control studies which are adjusted for smoking status.
CIs may vary slightly from those quoted in tables due to transformation during meta-analysis. COPD, chronic obstructive
pulmonary disease; MI, myocardial infarction.
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it is unclear how much of this increased risk is due to
smoking status. The included cohort study which
adjusted for smoking status showed an increased risk of
MI in people with COPD, but this was not apparent in
pooled analysis of the case–control studies which
adjusted for smoking status. Both of the included studies
which investigated the risk of MI associated with
AECOPD found an increased risk of MI in the weeks fol-
lowing AECOPD. Most studies which investigated mortal-
ity after an MI for patients with COPD as compared to
patients without COPD found that mortality after dis-
charge was greater for those with COPD, and an
increased risk of death was found on pooled analysis.
However, ﬁndings on in-hospital mortality after an MI
were mixed, and there was only weak evidence for
increased risk of death in hospital for patients with
COPD on pooled analysis.
Limitations of included studies and future work
One common limitation among the included studies,
particularly those which investigated the risk of MI asso-
ciated with COPD, was missing information on smoking
status. As smoking is very strongly associated with COPD
and risk of MI, it is likely to be a major confounder in
all studies investigating this association. All of the studies
in this review which investigated this association used
either clinical or administrative routine data sources.
Routine data are a potentially rich source of information
about huge numbers of patients. However, data on
smoking are not routinely recorded in all administrative
databases. Indeed, all of those studies which did not
have data for smoking in this question used
administrative databases. Future studies on the associ-
ation between COPD and cardiovascular disease should
use data sources which contain reliable information on
smoking status.
Further studies should be carried out to conﬁrm ﬁnd-
ings that AECOPD are periods of increased risk of MI
for people with COPD. These studies should ensure they
use validated exposure measures and are adequately
powered. Possible reasons for an increased risk of MI
during AECOPD include increased inﬂammation and
the potential cardiovascular effects of the drugs used to
treat AECOPD. If indeed the ﬁnding of increased risk
during AECOPD is conﬁrmed, future studies should
attempt to disentangle the reasons for increased risk of
MI. In addition, studies should investigate factors which
might modify this relationship, such as drugs used for
treatment of COPD and cardiovascular prevention.
Another potential bias in studies which investigate the
relationship between AECOPD and MI, which could
explain some of the increased risk of MI after AECOPD,
is differential misclassiﬁcation of episodes of angina as
AECOPD.
No studies were found which investigated the risk of
MI associated with the frequent exacerbator phenotype.
The frequent exacerbator phenotype may prove to be a
useful characteristic for stratifying cardiovascular risk
among patients with COPD. Future cohort studies of car-
diovascular disease in people with COPD should, where
possible, phenotype participants and investigate the rela-
tionship between exacerbator phenotype and risk of MI.
Few included studies assessed the inﬂuence of severity of
COPD on risk of MI; further research should investigate
Figure 8 Forest plot showing risk of death after discharge following MI for patients with COPD compared to patients without
COPD. Cis may vary slightly from those quoted in tables due to transformation during meta-analysis. COPD, chronic obstructive
pulmonary disease; MI, myocardial infarction.
Figure 7 Forest plot showing risk of in-hospital death following MI for patients with COPD compared to patients without COPD.
CIs may vary slightly from those quoted in tables due to transformation during meta-analysis. COPD, chronic obstructive
pulmonary disease; MI, myocardial infarction.
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this relationship as well as the inﬂuence of severity of
COPD on risk of death following MI.
A further limitation of several of the included studies
on death following MI was availability of information on
cause of death. Collection of information on cause of
death in future studies would allow investigators to draw
more conﬁdent conclusions about the reasons for
increased risk of death following MI for people with
COPD.
Strengths and limitations of this review
This review beneﬁtted from using a comprehensive
search strategy which covered several bibliographic data-
bases. As the relationship between AECOPD and MI has
not been extensively studied, the inclusion criteria for
this research question were kept purposively broad. This
allowed all information pertaining to this relationship to
be included in the evidence synthesis. One potential
limitation of systematic reviews is publication bias. The
potential for publication bias was highest for the review
of outcomes after MI. In order to reduce the risk of this
bias, we only included studies which speciﬁcally investi-
gated the risk of COPD on MI rather than several differ-
ent potential prognostic factors, as studies which
investigated several factors which did not ﬁnd an associ-
ation between COPD and MI may not have reported this
in the abstract or even in the text. Owing to clinical and
statistical heterogeneity, meta-analysis could only be con-
ducted for some of the research questions. Where
meta-analysis was conducted, statistical heterogeneity was
generally high, and this may limit the generalisability of
pooled estimates.
CONCLUSIONS
There is good evidence of an increased risk of MI in
people with COPD; however, it is unclear to what extent
this association is due to smoking status.
There is some evidence that among people with
COPD, AECOPD represent periods of increased risk of
MI. However, further larger studies using validated
exposure methods are needed to support this ﬁnding.
There is weak evidence that in-hospital mortality is
higher for people with COPD after an MI. There is
good evidence that postdischarge mortality after an MI
is higher for people with COPD.
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